Corey McCann, Pear Therapeutics CEO
March 31, 2022 01:23 PM EDT
Pharma

Pear Ther­a­peu­tics sets the stage for a fruit­ful 2022, fore­cast­ing a five-fold boost in rev­enue

Nicole DeFeudis

Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Trump says he'll sign or­der on 'most-fa­vored na­tion' drug price plans Mon­day

From deal to dis­as­ter: Drug­mak­ers face a changed Wash­ing­ton as Trump em­braces ‘most fa­vored na­tion’ prices

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

As­traZeneca re­ports Phase 3 win for Imfinzi; Roche to build new man­u­fac­tur­ing site in Chi­na

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times